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Engagement of the interleukin-1 (IL-1) and Toll-like
receptors triggers mitogen-activated protein kinase
(MAPK) pathways and activation of transcription fac-
tors such as NFB and AP-1. Recent studies have iden-
tified members of the Pellino protein family as novel
mediators in mediating activation of these pathways.
However, no evidence has been presented to date to
suggest a role for the Pellino proteins in activation of
the p38 MAPK pathway. We demonstrate herein that
Pellino3 is a strong activator of p38 MAPK. RNA inter-
ference was used to reveal a physiological role for Pel-
lino3 in the IL-1 pathway leading to activation of p38
MAPK. A series of N-terminal truncation and point mu-
tants of Pellino3 were generated and tested for their
ability to activate p38 MAPK in an effort to map sites of
protein interaction important for p38 MAPK activation.
In this way we show that the binding of Pellino3 to IL-1
receptor-associated kinase 1 coincides with its ability to
promote p38 MAPK activation. TRAF-6 and transform-
ing growth factor--activating kinase 1 are shown to act
as downstreammediators of the activation of p38 MAPK
by Pellino3. Finally we confirm the functional conse-
quences of the activation of p38 MAPK by Pellino3 by
demonstrating that Pellino3 promotes translocation of
the p38 substrate, MAPK-activated protein kinase2,
from the nucleus to the cytoplasm and activates the
transcription factor CREB in a p38 MAPK-dependent
manner. Our study not only identifies Pellino3 as a
novel upstream regulator of the p38 MAPK pathway but
also probes the mechanistic basis underlying the ability
of Pellino3 to promote activation of this pathway.
Human Toll-like receptors (TLRs)1 detect pathogen-associ-
ated molecular patterns (1–7) and share with the IL-1 receptor
a conserved cytoplasmic Toll/IL-1R homology (TIR) domain (8).
The engagement of these receptors allows for their TIR do-
mains to recruit the adapter protein Myd88 (9) and other TIR
domain containing adapter proteins such as MyD88 adapter-
like/TIR domain-containing adapter protein (10, 11), TIR do-
main-containing adapter-inducing interferon-/TIR-containing
adaptor molecule-1 (12, 13), and TIR domain-containing adapt-
er-inducing interferon--related adaptor molecule (14, 15).
Some of these adaptor proteins, such as Myd88, subsequently
recruit and activate members of the IL-1 receptor-associated
kinase (IRAK) family (16–20). The IRAK-Myd88 association
triggers hyperphosphorylation of IRAK leading to its dissocia-
tion from Myd88 and its interaction with the downstream
adaptor tumor necrosis factor receptor-associated factor 6
(TRAF-6) (21). This results in activation of transforming
growth factor--activating kinase 1 (TAK-1) leading to stimu-
lation of IB kinases and ultimately activation of NFB (22).
In addition to NFB activation, IL-1R1 and TLRs can also
initiate mitogen-activated protein kinase (MAPK) signaling
cascades and activate multiple transcription factors. Thus IL-1
and LPS induce phosphorylation of p38, ERK1/2, and JNK
(23–27). Although the mechanisms by which the MAPKs are
activated by IL-1R1 and TLRs are incompletely understood,
several upstream regulators have been identified, including
those that mediate activation of NFB. More specifically, TAK-
1/TAB1 can activate the MAPK kinases MKK3/6 and MKK4,
which in turn activate p38 and JNK, respectively (22).
Members of the novel Pellino protein family have recently
emerged as mediators in transducing signals in the IL-1R/TLR
pathways. Pellino was first identified inDrosophila by virtue of
its association with Pelle, the Drosophila homologue of IRAK
(28). Three mammalian homologues have since been identified
(29–33). Mammalian Pellino1 interacts with IRAK, IRAK4,
TRAF-6, and TAK-1 and is required for activation of NFB (30)
but is not involved in activation of the MAPK pathways (34).
Mammalian Pellino2 also interacts with these same proteins
(29, 35), and although there are contrasting reports on its
involvement in activation of NFB (29, 35), it has recently been
shown to promote activation of ERK1/2 and JNK (34). Human
Pellino3, both full-length and its alternative splice variant,
interacts with IRAK, TRAF-6, and TAK-1, but interestingly
fails to activate NFB demonstrating that members of the
Pellino family are not functionally redundant (31). However,
like Pellino2, Pellino3 activates ERK1/2 and JNK. Although
the latter MAPK pathways are activated by these Pellino pro-
teins, no evidence has been presented to date implying a role
for members of the Pellino family in activation of the p38
MAPK pathway. Indeed a role for Pellino1 and -2 in this path-
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way has already been excluded (31, 34). Because members of
the Pellino family are not functionally redundant we explored
the potential of Pellino3 to regulate the p38 MAPK pathway.
We show that Pellino3 is a novel activator of this pathway and
further demonstrate that Pellino3 activates CREB in a p38-de-
pendent manner. By generating a series of truncation mutants
of Pellino3 we map regions that positively influence p38 MAPK
activity and identify a crucial amino acid residue in Pellino3 for
IRAK1-Pellino3 association.
MATERIALS AND METHODS
Biological Reagents and Cell Culture—Anti-TRAF-6, anti-IRAK, and
anti-TAK-1 were from Santa Cruz Biotechnology. Monoclonal anti-myc
antibody was from Cell Signaling Technology. Constructs encoding
TRAF-6, TRAF-6 DN-(289–522), and IRAK-1 were from Tularik (San
Francisco, CA). TAK-1 was a gift from Dr. H. Sakurai (Tanabe Seiyaku
Co., Osaka, Japan). Dominant negative TAK-1 (K66W) was a gift from
Dr. Kunihiro Matsumoto (Nagoya University, Japan). The plasmids
encoding wild-type and dominant negative p38 MAPK were gifts from
Prof. R. J. Davis (University of Massachusetts Medical Center) and
have been described previously (36).
Parental HEK293 cells and HEK293 cells stably expressing TLR4 (gift
from Douglas T. Golenbock) were maintained in Dulbecco’s modified Ea-
gle’s medium supplemented with 10% (v/v) fetal bovine serum, penicillin
G (100 g/ml), and streptomycin (100 g/ml). G418 (Geneticin, 0.5 mg/ml)
was used as the selective agent for the stably transfected 293TLR4.
Cloning and Expression Vectors—Full-length and the alternative
spliced variant of Pellino3 (designated Pellino3L and Pellino3S, respec-
tively, in this report) were cloned from HEK293 cDNA. Pellino1 was
cloned from human placental cDNA. Pellino2 was cloned from HEK293
cDNA. All cloning used the GC-RICH PCR system (Roche Applied
Science) and primers for Pellino1, Pellino2, Pellino3L, and Pellino3S
were based on sequences deposited in GenBankTM (accession numbers
AF300987, NM_021255, AF487456, and AF487457, respectively). The
genes were tagged at the C terminus with the c-myc epitope tag and
subsequently cloned into the T/A cloning vector pTARGET (Promega
Biosciences, San Luis Obispo, CA) and a BamHI-XhoI-digested
pcDNA3.1/Zeo (Invitrogen) mammalian expression vector. Truncation
mutants of Pellino3L were generated by PCR using the GC-RICH PCR
system and cloned into the pTARGET and pcDNA3.1/Zeo mammalian
expression plasmids. Site-directed mutagenesis was performed using
Pfu Turbo (Stratagene, La Jolla, CA), and mutants were generated
according to the manufacturer’s instructions. The integrity of all gen-
erated clones was confirmed by sequencing. The MAPK-activated pro-
tein (MAPKAP) kinase 2 (accession no. BC036060) was amplified by the
GC-RICH PCR system, using HEK293 cDNA as template and cloned
into a modified pIRES-DsRed expression plasmid (BD Biosciences,
Clontech). The IRES was removed by a two-step process of first site-
directed mutagenesis followed by the release of a restriction fragment
containing the IRES thus allowing for the expression of a MAPKAP
kinase 2-DsRed fusion protein. Pellino constructs were additionally
subcloned into the EcoRI-digested pEGFP-N1 (BD Biosciences, Clon-
tech) vector for confocal analysis.
CHOP Reporter System—The PathDetect CHOP trans-Reporting Sys-
tem (Stratagene) was used, according to the manufacturer’s recommen-
FIG. 1. Pellino3L and Pellino3S activate the p38 MAPK pathway. A, HEK293 cells were co-transfected with the trans-activator plasmid
pFA-CHOP, pFR-Luc (encoding GAL4-CHOP regulated firefly luciferase), phRL-TK (constitutively expressed Renilla luciferase) and designated
amounts of plasmids encoding myc-tagged Pellino1, Pellino3S, or Pellino3L. Cell extracts were generated the following day and assayed for firefly
(a measure of CHOP transactivation and hence p38 MAPK activity) and Renilla (for normalizing transfection efficiency) luciferase. Data are
presented relative to cells transfected with empty vector (pTARGET) alone. Results represent mean  S.E. of six independent experiments. Inset
in A, HEK293 cells were transfected with plasmids encoding myc-tagged Pellino1, Pellino3S, or Pellino3L. Cell lysates were subjected to
polyacrylamide gel electrophoresis and subsequently to Western immunoblotting using anti-myc antibodies. Immunoreactivity was visualized by
enhanced chemiluminescence. B, HEK293 cells were transfected with various amounts of plasmids encoding Pellino3L (0.5, 1, and 1.6 g), Pellino1
(1.6 g), and MEK3 (1.6 g). The pTARGET empty vector (EV) was used as a negative control. Cell lysates were generated the following day,
subjected to polyacrylamide gel electrophoresis, and subsequently to Western immunoblotting using antibodies to detect levels of phosphorylated
and total p38 MAPK. C, HEK293 cells were co-transfected with a plasmid encoding wild-type p38 MAPK (1 g) and Pellino3L, Pellino1, MEK3,
or pTARGET empty vector (EV) (3 g). Cell lysates were generated the following day and immunoprecipitated using phospho-specific p38 MAPK
antibodies. Immunoprecipitates were incubated in kinase buffer with GST-ATF-2 and then subjected to Western immunoblotting using anti-
phospho-ATF-2 monoclonal antibody.
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dations, to measure activation of the p38 MAPK pathway. Briefly,
HEK293 TLR4 cells (2.6  104 cells/well) were seeded into 96-well plates
and grown for 24 h. Cells were then transfected, using GeneJuice trans-
fection reagent (Novagen, Madison, WI), with firefly luciferase reporter
plasmid pFR-Luc (60 ng), the trans-activator plasmid pFA-CHOP (acti-
vation domain of CHOP fused with the yeast Gal4 DNA binding domain,
1 ng), constitutively expressed Renilla-luciferase reporter construct
(phRL-TK, 20 ng, Promega Biosciences), varying amounts of expression
constructs. Total DNA was kept constant (230 ng/well) using the appro-
priate empty vector. The activation of CREB was assessed by performing
equivalent transfections using CREB-regulated luciferase (60 ng, BD
Biosciences, Clontech), phRL-TK plasmid (20 ng), and varying amounts of
expression constructs. Cell extracts were generated 24 h later using the
Reporter Lysis Buffer (Promega Biosciences), and extracts were assayed
for firefly luciferase and Renilla-luciferase activity using the Luciferase
Assay system (Promega Biosciences) and coelenterazine (1 g/ml, Insight
Biotechnology Ltd.), respectively.
Western Blot Analysis of p38 MAPK Phosphorylation—HEK293 cells
(3  105/well) were seeded into 12-well plates and grown for 24 h. Cells
were transfected, using Lipofectamine 2000 (Invitrogen), with various
amounts of plasmids encoding Pellino3L (0.5, 1, and 1.6 g), Pellino1 (1.6
g), Pellino3L Y44A (1.6 g), and MEK3 (1.6 g). The pTARGET empty
vector was used as a negative control. Cells were harvested in SDS sample
buffer the following day, resolved by SDS-PAGE, transferred to polyvi-
nylidene difluoride membranes, and probed for levels of phosphorylated
and total p38 using the PhosphoPlus p38 MAP Kinase (Thr-180/Tyr-182)
antibody kit as recommended by the manufacturer (New England Bio-
labs). Immunoreactivity was visualized by enhanced chemiluminescence.
Analysis of p38 MAPK Activity by in Vitro Kinase Assay—HEK293
cells (5  105/well) were seeded into 6-well plates and grown for 24 h.
Cells were co-transfected, using Lipofectamine 2000, with a plasmid
encoding wild-type p38 MAPK (1 g) and Pellino3L, Pellino3L Y44A,
Pellino1, MEK3, or pTARGET empty vector (3 g). At 24-h post-trans-
fection cells were lysed in 0.2 ml of lysis buffer (50 mM Tris-HCl (pH
7.5), 150 mM NaCl, 0.5% (v/v) Nonidet P-40, 50 mM NaF, 1 mM sodium
orthovanadate, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluo-
ride, protease inhibitor mixture (25 g/ml leupeptin, 25 g/ml aproti-
nin, 1 mM benzamidine, 10 g/ml trypsin inhibitor)). Lysates were then
assayed for p38 MAPK activity using a non-radioactive p38 (SAPK2a
kinase) activity assay kit as recommended by the manufacturer
(Chemicon International). Briefly, cell lysates were immunoprecipi-
tated using phospho-specific p38 MAPK antibodies. Immunoprecipi-
tates were incubated in kinase buffer with GST-ATF-2 and then sub-
jected to Western immunoblotting using anti-phospho-ATF-2
monoclonal antibody.
Suppression of Endogenous Expression of Pellino3—Pre-designed
small interfering RNA (siRNA) targeting Pellino3 was purchased from
Ambion Inc. (target sequence, GAG GAC AGA CTG TTA ACA AAT),
and a corresponding scrambled siRNA was designed and constructed
using the Silencer in Vitro transcription siRNA construction kit (Am-
bion Inc.). HEK293TLR4 cells were seeded into 12-well plates (3  105
cells/well) and transfected 24 h later, using Lipofectamine 2000, with
various concentrations of siRNAs (0–15 nM). Cells were treated 30 h
following transfection with IL-1 (10 ng/ml) for 20 min and then har-
vested in SDS sample buffer. Samples were probed for levels of phos-
phorylated and total p38 MAPK as described above. To confirm sup-
pression of endogenous expression of Pellino3, RNA was extracted from
cells, using the RNAqueous-4PCR kit (Ambion Inc.) and subsequently
reverse transcribed into cDNA using AMV-reverse transcriptase (Pro-
mega Biosciences). PCR was then performed on the cDNAs using
GAPDH-specific primers (GAPDH-for, 5-CCA TGC CAT CAC TGC
CAC CCA GAA-3; GAPDH-rev, 5-GTC CAC CAC CCT GTT GCT GTA
GCCG) and Pellino3-specific primers (Pellino3-for, 5-GGC TTC GAT
GCC TCT AGC AAC-3; Pellino3-rev, 5-CAGGCGGCA TGGAAAGCA
TG-3). PCR products were resolved on a 1% agarose gel.
Co-immunoprecipitation Analysis—HEK293 cells (5  105/well) were
seeded into 6-well plates and grown for 24 h. Cells were transfected, using
Polyfect (Qiagen), with the relevant Pellino construct (1.5 g) in the
presence or absence of expression plasmids encoding IRAK, TRAF-6, or
TAK-1 (0.5 g). At 24 h post-transfection cells were lysed in 0.5 ml of lysis
buffer (as above). Cellular debris was removed by centrifugation at
12,000  g for 10 min. An aliquot (50 l) of lysate was retained for
Western blot analysis. Pre-cleared cell lysates were incubated overnight
at 4 °C with monoclonal anti-myc antibody that had been pre-coupled
with Protein A/G-Sepharose beads. Following incubation, the beads were
centrifuged at 2,500 g for 5 min at 4 °C followed by five wash steps with
700 l of lysis buffer lacking the protease inhibitor mixture. The beads
were then resuspended in SDS sample buffer, separated by SDS-PAGE,
transferred to polyvinylidene difluoride membranes, and analyzed by
immunoblotting using the appropriate antibodies. Immunoreactivity was
visualized by enhanced chemiluminescence.
Confocal Microscopy—HEK293 cells (1.6  105/well) were seeded
into 4-well Lab-Tek chamber slides (Nunc A/S, DK-4000, Denmark) and
grown for 24 h. Cells were then transfected, using GeneJuice (Nova-
gen), with MAPKAP kinase 2-DsRed (400 ng) in the presence or absence
of Pellino3-pEGFP or Pellino3(Y44A)-pEGFP (400 ng). Cells were fixed
in 4% paraformaldehyde for 15 min, washed three times with phos-
phate-buffered saline, and mounted with Slowfade antifade reagent
(DAPI-containing medium, (1.5 g/ml, Molecular Probes, Inc.). Confocal
images were captured using the 63 objective (oil immersion) on the
UV Zeiss 510 Meta System laser scanning microscope equipped with
the appropriate filter sets and analyzed using the LSM 5 browser
imaging software.
RESULTS
Pellino3 Activates the p38 MAPK Pathway—To address the
ability of Pellino3 to activate the p38 MAPK pathway, HEK293
cells were co-transfected with increasing amounts of expression
plasmid encoding myc-tagged Pellino3L or Pellino3S and compo-
nents of the PathDetect CHOP trans-Reporting System. The
latter includes the GAL4-inducible promoter, pFR-Luc, and the
trans-activating fusion protein GAL4-CHOP. Because CHOP is a
substrate for p38 MAPK, and this leads to activation of its trans-
activation capacity (37), the expression of luciferase from pFR-luc
is an index of p38 MAPK activity. The overexpression of both
Pellino3L and Pellino3S caused a dose-dependent induction of
pFR-luciferase (Fig. 1A). Both forms exhibited comparable levels
of activation with maximum stimulation of 6- to 7-fold. This
represents a strong level of activation, because the maximum
-fold induction affected by the positive MEK3 driver is 10- to
12-fold (data not shown). In contrast, the overexpression of Pel-
lino1 failed to induce expression of luciferase (Fig. 1A) confirming
its previously published inability to activate the p38MAPK path-
way (34). This differential ability of Pellino3 versus Pellino1 to
activate the p38 MAPK pathway is not due to lack of expression
of the latter, because Western immunoblotting of lysates con-
firmed expression of both constructs (Fig. 1A, inset).
FIG. 2.Pellino3 is involved in IL-1 activation of p38.HEK293 cells
were transfected in the absence or presence of various concentrations of
siRNA specific for Pellino3 or a scrambled control siRNA (5–15 nM). Cells
were treated 30 h post transfection with or without IL-1 (10 ng/ml) for 20
min. A, cell lysates were generated, subjected to polyacrylamide gel elec-
trophoresis, and subsequently to Western immunoblotting. Blots were
first probed with phospho-specific p38 antibodies and then stripped and
re-probed using total p38 antibodies. Immunoreactivity was visualized by
enhanced chemiluminescence. B, total cellular RNA was prepared and
subjected to RT- PCR using primers to selectively amplify regions of the
Pellino3 and GAPDH cDNAs. This resulted in the generation of products
with the predicted sizes of 650 and 400 bp, respectively.
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Two additional independent assay systems were further em-
ployed to validate the CHOP reporter system and confirm that
Pellino3 activates p38 MAPK. MEK3 was used as a positive
driver in both assays. Firstly, cells were transfected with in-
creasing amounts of an expression vector encoding Pellino3L,
and cell extracts were assayed for levels of phosphorylated p38
MAPK using an antibody that detects doubly phosphorylated
threonine 180 and tyrosine 182 of p38 MAPK. Cells showed
some basal phosphorylation of p38 MAPK. However Pellino3L
caused a dose-dependent increase in the levels of phosphoryl-
ated p38 MAPK, whereas Pellino1 was ineffective (Fig. 1B). As
control for the assay, all samples showed equivalent levels of
total p38 MAPK as judged by Western immunoblotting analy-
sis using control antibodies that recognize p38 irrespective of
its phosphorylation status.
An in vitro kinase assay for p38 MAPK was also used to
further confirm its activation by Pellino3. Thus cells were
transfected with Pellino3L, cell extracts were immunoprecipi-
tated with phospho-p38 MAPK antibodies, and immunoprecipi-
tates were assayed for their ability to catalyze the in vitro
phosphorylation of the p38 MAPK substrate ATF-2. Immuno-
precipitates from Pellino3L-transfected cells showed increased
activity with respect to phosphorylation of ATF-2 (Fig. 1C). In
contrast, Pellino1-transfected cells demonstrated comparable
activity with cells transfected with empty vector. This assay, in
conjunction with the other two systems, strongly confirms Pel-
lino3 as a robust activator of p38 MAPK.
Pellino3 Mediates IL-1 Activation of p38 MAPK—To address
the physiological role of Pellino3 in the p38 MAPK pathway,
siRNA that specifically targets Pellino3 was assessed for its
effects on the IL-1-induced phosphorylation of endogenous p38
MAPK in HEK293 cells. Pellino3-specific siRNA caused a con-
siderable reduction in the phosphorylation of p38 MAPK by
IL-1, relative to a control Pellino3-scrambled siRNA (Fig. 2A).
Neither siRNA had any effect on the levels of total p38 MAPK.
To validate selective suppression of endogenous Pellino3 ex-
pression by the Pellino3-specific siRNA, RNA samples from
siRNA-transfected cells were assayed for levels of Pellino3 and
GAPDH mRNAs by reverse transcription-PCR analysis (Fig.
2B). The scrambled siRNA sequence had no effect on the mRNA
levels of Pellino3 relative to cells that had been transfected in
the absence of any siRNAs. In contrast the Pellino3-specific
siRNA caused a strong suppression of Pellino3 mRNA expres-
sion and left barely detectable levels. Neither siRNA affected
the levels of the housekeeping GAPDH mRNA.
Deletion Analysis of Pellino3 Reveals Sites Important for p38
MAPK Activation—We next attempted to identify the struc-
tural basis underlying the unique ability of Pellino3, as the
only member of the Pellino family, to activate the p38 MAPK
pathway. The alignment of the protein sequences encoded by
the mammalian Pellino genes demonstrates that greatest se-
quence divergence occurs at their N termini (Fig. 3A). Further-
more, both forms of Pellino3 are longer at their N termini by 27
amino acids. Using Pellino3L as a reference, a series of trun-
cation mutants were generated in an effort to identify key
regions of importance to activating p38 MAPK. Emphasis was
placed on regions that show greatest sequence divergence be-
tween Pellino3 and the other Pellino members. All mutants
were assessed for their ability to activate p38 MAPK using the
CHOP trans-Reporting System. The truncation of the first 27
amino acids failed to affect the ability of Pellino3 to activate
p38 MAPK, because both full-length Pellino3 and mutant 28–
469 showed comparable patterns of dose-dependent activation
in the assay (with both demonstrating maximum induction of
6-fold) (Fig. 3B). The next 9 and 15 amino acids were addition-
ally truncated, because these regions show sequence diver-
FIG. 3. Mapping studies identify regions important for Pellino3 activation of p38 MAPK. A, the alignment of the N-terminal regions of
Pellino1, -2, and -3 and the initiation sites for Pellino3L truncationmutants are indicated (Pellino3L135–469 not presented). Sequence alignments were
constructed using ClustalW and displayed using BOXSHADE. B, HEK293 cells were co-transfected with the trans-activator plasmid pFA-CHOP,
pFR-Luc (encoding GAL4-CHOP regulated firefly luciferase), phRL-TK (constitutively expressed Renilla luciferase), and designated amounts of
plasmids encoding myc-tagged Pellino3L and truncation mutants of Pellino3L. Cell extracts were generated the following day and assayed for firefly
(a measure of CHOP transactivation and hence p38 MAPK activity) and Renilla (for normalizing transfection efficiency) luciferase. Data are presented
relative to cells transfected with empty vector (pTARGET) alone. Results represent mean  S.E. of five independent experiments.
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gence between Pellino3 and the other members of the family.
These truncation mutants, 37–469 and 43–469, indeed showed
reduced efficacy in activating p38 (5- and 3.5-fold, respectively,
compared with 6-fold with wild-type construct) indicating that
sites important for augmenting p38 MAPK activity lie within
this stretch of 15 amino acids (Fig. 3B). However, the removal
of the next 5 amino acids obliterated the ability of Pellino3 to
activate p38 MAPK as evidenced by the complete ineffective-
ness of mutants 48–469 and 135–469 in the assay (Fig. 3B).
The inability of these mutants to activate p38 MAPK is not due
to lack of expression (see below in Fig. 5).
The results of these transfection studies define a critical
region (residues 43–47; KYGEL) in Pellino3 for manifesting
activation of p38 MAPK. We next performed site-directed mu-
tagenesis to identify specific individual residues in this region
that are key to manifesting the activity. We initially mutated
the lysine to alanine and this mutant was fully active in the
CHOP transfection assay (data not shown). However the mu-
tation of the immediately adjacent tyrosine residue (Tyr-44) in
Pellino3L abolished its ability to activate p38 MAPK (Fig. 4A).
This loss in activity was independent of the type of mutation,
because mutation to phenylalanine or alanine leads to similar
obliteration of activity. The crucial importance of Tyr-44 with
respect to Pellino3 activation of p38 MAPK was further con-
firmed by demonstrating that mutation of this residue abol-
ishes the ability of Pellino3 to induce phosphorylation of en-
dogenous p38 MAPK (Fig. 4B) and thus leaves Pellino3
incapable of activating p38 MAPK to phosphorylate substrates
such as ATF-2 (Fig. 4C). In an effort to explore the potential
regulation of Pellino3 activity by phosphorylation of Tyr-44 we
mutated the latter to the phospho-mimetic residue glutamic
acid. However, the resulting mutant was inactive (Fig. 4A)
questioning the importance of phosphorylation of this residue
for activation of Pellino3.
Pellino3-IRAK1 Interaction Coincides with Pellino3 Activa-
tion of p38 MAPK—The mechanistic basis to the capacity of
Pellino3 and its mutated forms to activate the p38 MAPK
pathway was next explored. Because it was previously shown
that Pellino3 interacts with IRAK, TRAF-6, and TAK-1 (31),
expression constructs encoding these same proteins were co-
transfected with myc-tagged Pellino3 or truncated/mutated
forms and examined for their potential to interact (Fig. 5).
Pellino3 proteins were immunoprecipitated from cell lysates
with anti-myc antibody, and the immunoprecipitates were
probed for the presence of TRAF-6, TAK-1, and IRAK. These
studies demonstrated that full-length Pellino3 and the trun-
cated/point mutant constructs described above all retained the
ability to interact with TRAF-6 (Fig. 5A) and TAK-1 (Fig. 5B).
This implies that the binding site(s) on Pellino3 for these pro-
teins lie downstream of amino acid 134. The interaction of the
various Pellino3 proteins with IRAK was next assessed (Fig.
5C). Intriguingly full-length Pellino3 and the truncation mu-
tants that retained the ability to activate p38 MAPK pathway
co-precipitated with IRAK, whereas truncation mutants that
were ineffective in the p38 MAPK assay failed to associate with
IRAK. Furthermore, the site-directed mutagenesis of Y44A
FIG. 4.Mutational analysis of tyrosine residue in the N terminus of Pellino3 abrogates its ability to activate p38 MAPK. A, HEK293
cells were co-transfected with the trans-activator plasmid pFA-CHOP, pFR-Luc (encoding GAL4-CHOP regulated firefly luciferase), phRL-TK
(constitutively expressed Renilla luciferase), and designated amounts of plasmids encoding myc-tagged Pellino3L or site-directed mutants. Cell
extracts were generated the following day and assayed for firefly (a measure of CHOP transactivation and hence p38 MAPK activity) and Renilla
(for normalizing transfection efficiency) luciferase. Data are presented relative to cells transfected with empty vector (pTARGET) alone. Results
represent mean  S.E. of three independent experiments. B, HEK293 cells were transfected with plasmids encoding Pellino3L, Pellino3L Y44A,
MEK3, or pTARGET empty vector (EV) (1.6 g). Cell lysates were generated the following day and subjected to Western immunoblotting using
antibodies to detect levels of phosphorylated and total p38 MAPK. C, HEK293 cells were co-transfected with a plasmid encoding wild-type p38
MAPK (1 g) and Pellino3L, Pellino3L Y44A, MEK3, or pTARGET empty vector (EV) (3 g). Cell lysates were generated the following day and
immunoprecipitated using phospho-specific p38 MAPK antibodies. Immunoprecipitates were incubated in kinase buffer with GST-ATF-2 and then
subjected to Western immunoblotting using anti-phospho-ATF-2 monoclonal antibody.
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abolished the ability of Pellino3 to interact with IRAK. The
expression of IRAK and the various myc-tagged Pellino3 pro-
teins was confirmed by Western immunoblotting of cell lysates
(middle and bottom panels, respectively).
The above findings emphasize the crucial importance of
Tyr-44 in Pellino3 for its ability to interact with IRAK. Inter-
estingly this tyrosine residue is conserved in both Pellino1 and
-2, and although both can interact with IRAK, neither can
activate p38 MAPK. We explored the importance of the tyro-
sine residue in Pellino1 and -2 with respect to their interaction
with IRAK (Fig. 6, A and B, respectively). Thus wild-type forms
of both Pellino1 and -2 and their respective Y17A and Y19A
mutants were assessed for their interaction with IRAK (Fig. 6).
Interestingly the mutants mirrored their wild-type counter-
parts with respect to their ability to interact with IRAK sug-
gesting that the tyrosine residue is of unique importance in
Pellino3, whereas it is dispensable in Pellino1 and -2, at least
with respect to facilitating interaction with IRAK.
Activation of p38 MAPK by Pellino3 Is Mediated by TRAF-6
and TAK-1—The downstream signaling components employed
by Pellino3 in its activation of p38 MAPK was next addressed.
As stated above, TRAF-6 and TAK-1 are known to act down-
stream of IRAK and upstream of p38, and these signaling
molecules present themselves as lead candidates for mediating
the activation of p38 by Pellino3. This was directly examined by
measuring the regulatory effects of dominant negative forms of
TRAF-6 and TAK-1 on Pellino3 activation of p38 MAPK in the
GAL4-CHOP-based assay (Fig. 7). Both dominant negative con-
structs completely blocked the ability of Pellino3 to activate
p38 MAPK indicating key roles for TRAF-6 and TAK-1 as
downstream mediators of Pellino3 signaling.
Pellino3 Triggers Translocation of MAPKAP Kinase 2 from
the Nucleus to the Cytoplasm—The functional consequence of
p38 MAPK activation by Pellino3 was finally assessed. The
best characterized substrate for activated p38 MAPK is MAP-
KAP kinase 2 (24). The latter is normally resident in the
nucleus but translocates to the cytoplasm upon its phosphoryl-
ation and activation by p38 MAPK (38, 39). We thus investi-
gated the potential of Pellino3 to promote the nuclear export of
MAPKAP kinase 2. This was performed by the initial engineer-
ing of expression constructs encoding the fusion proteins MAP-
KAP kinase 2-DsRed (DsRed is a variant of Discosoma sp. red
fluorescent protein) and Pellino3-pEGFP. HEK293 cells were
transfected with MAPKAP kinase 2-DsRed in the presence or
absence of Pellino3-pEGFP, and cells were subsequently
viewed by confocal microscopy. Cells, in which MAPKAP ki-
nase 2-DsRed was expressed in the absence of Pellino3-pEGFP,
showed red fluorescence with predominance in the nucleus
(Fig. 8A, lower left panel) as evidenced by co-localization with
the DAPI-stained nuclei (Fig. 8A, lower right panel). In con-
trast the co-expression of Pellino3-pEGFP showed a dramatic
reduction of red fluorescence in the nucleus with concomitant
increase in the cytoplasm of those cells that express Pellino3-
pEGFP (Fig. 8B, lower left panel). Indeed the redistribution of
MAPKAP kinase 2-DsRed from the nucleus to the cytoplasm
manifested as yellow staining in the montage (Fig. 8B, lower
right panel) due to the combined green and red fluorescence of
Pellino3-pEGFP and MAPKAP kinase 2-DsRed, respectively.
FIG. 5. Mapping regions in Pellino3 that facilitate interaction
with TRAF-6, TAK-1, and IRAK. HEK293 cells were co-transfected
with the designated myc-tagged Pellino constructs or the pTARGET
empty vector (EV) and TRAF-6 (A) or TAK-1 (B) or IRAK (C) expression
construct. Control cells were mock transfected (Mock) in the presence of
pTARGET alone. Cell lysates were generated and immunoprecipitated
with an immobilized anti-myc antibody. Immunoprecipitates were sub-
jected to Western immunoblotting using the appropriate antibody against
TRAF-6 (A) or TAK-1 (B) or IRAK (C). Cell lysates were also analyzed by
Western immunoblotting to confirm expression of the constructs.
FIG. 6. Mutation of conserved tyro-
sine residue in the N termini of Pel-
lino1 (A) and Pellino2 (B) fails to af-
fect their interaction with IRAK.
HEK293 cells were co-transfected with
the designated myc-tagged Pellino con-
structs or the pTARGET empty vector
(EV) and IRAK expression construct.
Control cells were mock transfected
(Mock) in the presence of pTARGET
alone. Cell lysates were generated and
immunoprecipitated with an immobilized
anti-myc antibody. Immunoprecipitates
were subjected to Western immunoblot-
ting using an anti-IRAK antibody. Cell
lysates were also analyzed by Western
immunoblotting to confirm expression of
the constructs.
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Interestingly, Pellino3-pEGFP showed intense expression in as
yet undefined structure(s) in the cytoplasm of the cell (Fig. 8B,
upper right panel). We also designed a Pellino3(Y44A)-pEGFP
fusion construct and co-transfected with MAPKAP kinase
2-DsRed. In contrast to wild-type Pellino3 the Y44A mutant
failed to promote the nuclear export of MAPKAP kinase
2-DsRed (Fig. 8C, lower left panel). The lack of significant
redistribution to the cytoplasm is evidenced by the absence of
yellow fluorescence in the montage (Fig. 8C, lower right panel).
This is consistent with the inability of Pellino3 (Y44A) to acti-
vate p38 MAPK. The expression of the Pellino3(Y44A)-pEGFP
mutant was represented as a more diffuse pattern (Fig. 8C,
FIG. 7. Pellino3 activates p38 MAPK
via TRAF-6 and TAK-1. HEK293 cells
were co-transfected with the trans-activa-
tor plasmid pFA-CHOP, pFR-Luc (encod-
ing GAL4-CHOP regulated firefly lucifer-
ase), phRL-TK (constitutively expressed
Renilla luciferase), and plasmids encod-
ing Pellino3L or Pellino3S (50 ng) in the
presence or absence of dominant negative
TRAF-6 or TAK-1 constructs (100 ng).
Cell extracts were generated the follow-
ing day and assayed for firefly (a measure
of CHOP transactivation and hence p38
MAPK activity) and Renilla (for normal-
izing transfection efficiency) luciferase.
Data are presented relative to cells trans-
fected with empty vector (pTARGET)
alone. Results represent mean  S.E. of
four independent experiments.
FIG. 8. Pellino3 promotes the nuclear export of MAPKAP kinase 2. HEK293 cells were co-transfected with MAPKAP kinase 2-DsRed and
pTARGET empty vector (A), Pellino3-pEGFP (B), or Pellino3 (Y44A)-pEGFP (C). Confocal images were captured using the 63 objective (oil
immersion) on the UV Zeiss 510 Meta System laser scanning microscope equipped with the appropriate filter sets and analyzed using the LSM 5
browser imaging software. The upper left panels indicate DAPI staining of the nuclei. The upper right panels represent images of isolated pEGFP
fluorescence. The lower left panels indicate images of isolated MAPKAP kinase 2-DsRed fluorescence. The lower right panels are montages of the
three other images.
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upper right panel) relative to Pellino3-pEGFP. Although the
basis of this different pattern of expression is not understood at
present, it is intriguing to speculate that the regions of intense
expression of wild-type Pellino3 may represent the formation of
macromolecular signaling complexes containing high concen-
trations of Pellino3.
Pellino3 Activates CREB in a p38 MAPK-dependent Man-
ner—Finally the functional consequence of MAPKAP kinase 2
activation by Pellino3 was confirmed by examining the ability
of Pellino3 to activate the transcription factor CREB. The latter
is a substrate for MAPKAP kinase 2 (40). Both full-length and
the alternative spliced variants of Pellino3 were overexpressed
in HEK293 cells and measured for regulatory effects on expres-
sion of a co-transfected CREB-regulated reporter construct.
Both forms induced expression of the luciferase reporter with
maximal induction of 5- to 6-fold (Fig. 9A). In contrast Pellino1
was ineffective, and this is likely due to its inability to activate
p38 MAPK. Indeed the role of p38 MAPK in mediating activa-
tion of CREB was confirmed by demonstrating that a dominant
negative form of p38 inhibits the activation of the CREB re-
porter by Pellino3 (Fig. 9B). Furthermore, all of the Pellino3
mutants were examined for their regulation of CREB activity,
FIG. 9. Pellino3 activates CREB in a
p38 MAPK dependent manner.
HEK293 cells were co-transfected with a
CREB-regulated firefly luciferase re-
porter, phRL-TK (constitutively ex-
pressed Renilla luciferase), and the fol-
lowing expression plasmids: A, Pellino1,
Pellino3L, or Pellino3S; B, Pellino3L or
Pellino3S (100 ng) with or without a con-
struct encoding dominant negative p38
(p38DN) (70 ng); C, Pellino3L or its des-
ignated mutants. Cell extracts were gen-
erated the following day and assayed for
firefly (a measure of CREB transactiva-
tion) and Renilla (for normalizing trans-
fection efficiency) luciferase. Data are
presented relative to cells transfected
with pCMV5 empty vector alone. Results
represent mean  S.E. of four independ-
ent experiments.
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and this experiment demonstrated a perfect correlation be-
tween the ability to stimulate p38 MAPK and promote activa-
tion of CREB (Fig. 9C). This is reflected with the finding that
the Y44A mutant is completely ineffective in activating CREB.
These findings clearly show that activation of CREB is a down-
stream functional consequence of the stimulation of p38 MAPK
by Pellino3.
DISCUSSION
This study demonstrates that Pellino3 is a novel upstream
activator of the p38 MAPK pathway. By using RNA interfer-
ence we also show a physiological role for Pellino3 in mediating
IL-1 activation of p38 MAPK. In the Pellino protein family, the
ability of Pellino3 to activate p38 MAPK appears to be unique,
because a previous report has demonstrated that Pellino1 and
-2 are ineffective in promoting activation of p38 MAPK (34).
Indeed the present report confirms the inability of Pellino1 to
activate this pathway. This study emphasizes that the mem-
bers of the Pellino family are not functionally redundant, and
the different members may play specific roles in activating
selective pathways. It is interesting to note that both full-
length and the alternative spliced variant of Pellino3 showed
comparable efficacy in activating p38 MAPK and to date there
are no known functional differences between the variants. The
functional consequences of the activation of the p38 MAPK
pathway by Pellino3 was also confirmed by demonstrating the
nuclear export of MAPKAP kinase 2 in response to overexpres-
sion of Pellino3. MAPKAP kinase 2 is an immediate substrate
for activated p38 MAPK, and the activation and nuclear export
of MAPKAP kinase 2 are regulated by its phosphorylation (24,
38). The consequence of MAPKAP kinase 2 activation was also
defined by demonstrating that Pellino3 activates the transcrip-
tion factor CREB in a p38 MAPK-dependent manner. These
studies thus identify a new signaling module consisting of
upstream Pellino3 and the downstream sequential activation of
p38 MAPK, MAPKAP kinase 2, and CREB.
Because Pellino3 is the only member of the Pellino family to
promote activation of p38 MAPK, we attempted to identify
unique characteristics of Pellino3 that may be associated with
this activity. More specifically we compared the primary struc-
ture of Pellino3 with Pellino1 and -2, and the multiple sequence
alignment clearly showed that most sequence divergence was
present at their N termini. Furthermore, Pellino3 has an ad-
ditional 27-amino acid region at its N terminus, and this was
the lead candidate for conferring unique properties on Pellino3.
However, the truncation of this region failed to affect the po-
tential of Pellino3 to activate the p38 MAPK pathway, and thus
the functional relevance of the region awaits further charac-
terization. The next 15 amino acids in Pellino3 showed some
sequence divergence with Pellino1 and -2. The truncation of
this region showed a reduction in Pellino3 activation of p38
MAPK that would imply the existence of important residues
within this region. However, the further truncation of the im-
mediately adjacent KYGEL residues caused complete loss of
p38 MAPK activation. The mechanistic basis to this finding
was addressed by probing the potential of Pellino3 and its
various mutants to interact with IRAK, TRAF-6, and TAK-1.
These proteins were chosen as lead candidates, because they
have previously been shown to interact with Pellino3 (31) and
act as upstream regulators of p38 MAPK (22). The mutants
that were ineffective in activating p38 were incapable of asso-
ciating with IRAK, whereas full-length Pellino3 and its active
mutants interacted with IRAK. The co-immunoprecipitation
studies mapped the tyrosine residue Tyr-44 in Pellino3 as a
critical residue for establishing protein-protein interactions
with IRAK. It is highly unlikely that the inability of Y44A to
interact with IRAK is due to nonspecific long range effects,
because it retained the ability to interact with TRAF-6 and
TAK-1. The co-immunoprecipitation assays indicate that the
binding site(s) for TRAF-6 and TAK-1 are located at the C
terminus or at least downstream of residue 134. Both TRAF-6
and TAK-1 are key downstream mediators of Pellino3, because
their dominant negative counterparts abolished Pellino3 acti-
vation of p38 MAPK. Interestingly, Pellino1 and -2 have pre-
viously been shown to interact with IRAK, TRAF-6, and TAK-1
(30, 31, 35), but neither can activate p38 (34). Thus while the
present studies propose that the interactions of Pellino3 with
these signaling proteins are crucial for triggering activation of
p38 MAPK, the ineffectiveness of Pellino1 and -2 would suggest
that interaction with these proteins is not sufficient to drive the
pathway. Pellino3 must interact with additional undefined pro-
teins that contribute to its ability to engage the p38 pathway.
Tyrosine residue 44 in Pellino3 is likely to be of major impor-
tance in facilitating such interactions. The present studies
show that this tyrosine residue, although conserved in all mem-
bers of the Pellino family, is uniquely important in Pellino3, at
least with respect to facilitating interaction with IRAK. This
tyrosine residue may also emerge to confer on Pellino3 the
exclusive capacity to interact with other proteins that are nec-
essary for triggering activation of the p38 MAPK pathway.
Thus Pellino3 is likely to act as a scaffold protein that recruits
a number of proteins to form a signaling complex, and the full
complement of proteins in this complex is required to trigger
downstream signaling.
Because tyrosine residues are subject to phosphorylation, we
attempted to address the potential regulation of Pellino3 func-
tion by phosphorylation of Tyr-44. We thus mutated Tyr-44 to
the phospho-mimetic residue glutamic acid. This mutant was
inactive. Although this may immediately suggest that phospho-
rylation of Tyr-44 may lead to inactivation of Pellino3, the
inactive nature of the Y44A mutant that cannot be phospho-
rylated at this residue would equivocate this proposal. Further-
more, although the side chain of glutamic acid mimics a phos-
phate group, it lacks the aromatic ring of tyrosine, and the
phosphorylation of the ring may be crucially important.
In summary this study identifies Pellino3 as a novel up-
stream regulator of the p38 MAPK and emphasizes that mem-
bers of the Pellino family are not functionally redundant. It
also delineates the downstream effectors and consequences of
Pellino3 signaling.
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